GMP Pharmaceuticals has completed extensive renovations to its global headquarters in Sydney, which now features a series of new facilities such as the dry manufacturing facility and a coating machine designed for processing higher volume batches.
New features and improvements to the Huntingwood facility also include a new wet granulation suite that would enable GMP to perfectly control the uniformity of micro-dosed multivitamins, minerals, and other functional ingredients by forging granules from fine powder particles, which eventually can be processed into a different downstream product such as tablets and sachets packaging form.
New packaging lines have also been put in place to pack powders into pillow packs and pouch packaging formats.
In addition to the new enhancements, GMP recently received a license from the US Food and Drug Administration for Food Facility Registration.
“These improvements will enhance the efficiency and productivity of our operations, bringing enormous benefits to our customers and staff alike. We are committed to investing in the latest technology and equipment to ensure that we remain at the forefront of our industry,” said Wei Keong, GMP’s Huntingwood Site Manager.
GMP also updated its TGA license variation to include new dosage forms such as effervescent tablets, enteric-coated tablets, film-coated tablets, modified-release tablets, granules, and hard capsules.
The Huntingwood site was first opened in 2019 and enabled GMP to be the first of its kind in Australia to produce and manufacture pharmaceutical-grade freeze-dried dairy, health, and functional food products for the domestic and overseas markets.
“With the global health and wellness market expected to continue to boom in the coming years, it is likely that the demand for Australian-made products will continue to rise. We see GMP as playing an important role in bringing local products to market, and seeing Australian businesses thrive,” Lee said.
